Investor Newsletter

Issue 10 2024

MicroPort®

MicroPort® MicroImaging Intravascular Ultrasound (IVUS) System and Catheter Receive NMPA Clearance, Enhancing Precision in Coronary Interventions

On October 16th, MicroPort® MicroImaging, a subsidiary of MicroPort Scientific Corporation (00853.HK), obtained approval from the National Medical Products Administration (NMPA) for the marketing of its Decypher™ IVUS Diagnostic System (Registration # 20243062024) and Outsight® Disposable IVUS Diagnostic Catheter (Registration # 20243062034).

The Decypher™ IVUS Diagnostic System set a new standard in the market with a pullback speed of up to 40mm/s, compared to the maximum of 10mm/s pullback speed found in other commercial IVUS systems. This allows for the fastest scan (image acquisition) of a 100mm-length vessel in just 3 seconds, all while providing sharp images with up to 20μm resolution. Meanwhile, the Outsight® Disposable IVUS Diagnostic Catheter, recognized for its superior crossability and compatibility, effectively addresses various vascular lesions, allowing for quick and accurate diagnostic decisions.

The approval of the Decypher™ and the Outsight® in China provides clinicians with advanced solutions for PCI diagnostics and treatment. Moving forward, MicroPort® MicroImaging will continue to prioritize innovation, committing to providing safe, high-quality medical imaging and diagnostic equipment to patients and doctors worldwide.



MicroPort® CRM Launches the First Ever Locally Produced ICD in China

Recently, the PLATINIUM™ implantable cardioverter defibrillators (ICD), produced by MicroPort® CRM Shanghai (MicroPort Soaring CRM (Shanghai) Co., Ltd.), an associated company of MicroPort® CRM, received approval from China's National Medical Products Administration (NMPA). This marks the first ICD manufactured in China to gain approval for market launch and is set to be officially commercialized within the country.

The approved ICDs include two models: the dual-chamber PLATINIUM™ DR 1540 and the single-chamber PLATINIUM™ VR 1240. The PLATINIUM™ single-chamber ICD is expected to have a lifespan exceeding 14 years, while the dual-chamber ICD is anticipated to last over 13 years. This exceptional longevity significantly reduces the frequency of device replacements, thereby lowering the risk of complications associated with replacement surgeries. Additionally, the product is equipped with an advanced atrioventricular relationship-based discrimination algorithm (PARAD+™), which accurately identifies supraventricular tachycardia to avoid misdiagnosis and inappropriate treatment. Furthermore, the proprietary BTO™ algorithm enables physiological pacing for patients within the tachycardia zone.

MicroPort

MicroPort® Orthopedics Hosts Third Annual Global Medial-Pivot Symposium in London

From October 11 to 12, MicroPort® Orthopedics (MPO) hosted the third Global Medial-Pivot Symposium in London. This was the largest medical education event run by the company, drawing more than 300 healthcare professionals from 31 countries.

The symposium was led by a committee of world-renowned orthopedic surgeons, including Dr. Philippe Van Overschelde (Ghent, Belgium), James Nace, DO, FAOAO, MPT (Baltimore, USA), Samuel J MacDessi MBBS (Hons) (Sidney, Australia), Professor John Skinner (Stanmore, UK), and Professor Theofilos Karachalios (Larissa, Hellenic Republic).

The first day focused on lectures delivered by renowned global key opinion leaders providing the latest clinical evidence on proven performances of the Medical-Pivot knee kinematics, personalized approach to patient care, and robust advanced technology platform.

The second day consisted of parallel breakout sessions, diving into practical applications of these themes and showcasing MPO's innovative solutions. Attendees had the opportunity to participate in round-table discussions on difficult cases treated with a medial-pivot knee solution, engage in live debate among faculty members with audience polling questions on alignment approaches, and attend a demo on the SkyWalker™ robotic platform followed by a discussion on the importance of data and the role of AI in orthopedics.

MicroPort

MicroPort® CardioFlow's Strategic Partner 4C Medical Commences the Pivotal Clinical Trial for AltaValve™ Transcatheter Mitral Valve Replacement Device

Recently, the AltaValve™ system, a transcatheter mitral valve replacement (TMVR) device developed by MicroPort® CardioFlow's strategic partner 4C Medical, initiated a pivotal clinical trial in Europe and the United States. The trial, named ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation), aims to evaluate the safety and efficacy of the AltaValve™ system in treating patients with moderate-to-severe or severe mitral regurgitation (MR) who are unsuitable for surgery or transcatheter edge-to-edge repair (NCT06465745). The result will support its CE marking and FDA approval.

The AltaValve™ system is currently the world's only fully retrievable and low-profile TMVR system, poised to offer the world's first atrial-only fixation MR treatment solution upon its market release. Its innovative design effectively addresses the mitral annular anchoring challenges present in current TMVR technologies, protecting the patient's heart structures during the procedure and minimizing the risk of left ventricular outflow tract obstruction or damage, resulting in safer and more superior clinical outcomes. In addition, the system employs a one-step release and positioning mechanism, simplifying the procedure and significantly shortening the learning curve for clinicians. Earlier this year, the AltaValve™ system was granted two Breakthrough Device designations by FDA, covering the indications for "moderate to severe or severe MR" and "moderate to severe or severe MR with moderate/severe mitral annular calcification."



MicroPort® MedBot™'s Toumai® Surgical Robot System Completes Multiple Landmark Robotic Telesurgery Cases in Sub-Sahara Africa in the Republic of Angola

MicroPort® MedBot™ (HKSE:2252) announced that the company successfully completed 6 robot-assisted laparoscopic radical prostatectomy procedures in the Republic of Angola. The surgical cases were performed by Dr. Vipul Patel, a world renowned robotic urologist surgeon, having personally performed over 18,000 robotic prostatectomies, and his surgical team based out of the Global Robotics Institute at AdVent Health in Celebration, Florida, in the United States of America. The urology surgeries were performed at Complexo Hospitalar de Doenças Cardio-Pulmonar Cardeal Dom Alexandre do Nascimento (Cardeal) which is located in the city of Luanda and has been established as a national health reference center for Angola.

From these 6 successful surgical cases and for the first time in the sub-Sahara Africa region, two of the cases were performed remotely using Toumai®'s telesurgery capability. The total latency time between the master and the remote systems for these robotic surgical cases was less than 6 milliseconds.

"My team came here to Angola to help the country for a great humanitarian purpose. The potential of robotics, remote surgery and education is the future of healthcare equity for countries such as Angola, " said Dr. Vipul Patel, "By being able to operate remotely, we have demonstrated for the first time in Africa the potential route for future humanitarian success."

MicroPort® MedBot™ SkyWalker™ Orthopedic Surgical Robot Gets Approval in Japan

On September 26, the SkyWalker™ Orthopedic Surgical Robot (SkyWalker™), developed by MicroPort® NaviBot®, an associated company of MicroPort® MedBot™, received market approval from the Japanese Ministry of Health, Labour and Welfare (MHLW).

The SkyWalker™ robot features platform integration, standardization, precision, and personalization, making it an ideal assistant for total knee arthroplasty (TKA) procedures. Equipped with lightweight medical robotic arms and featuring the world's first all-in-one osteotomy guide, it enables more efficient and precise bone cutting. This innovation not only significantly shortens the learning curve for surgeons, but also greatly improves surgical efficiency.

To date, SkyWalker™ has received market approval from regulatory authorities in eight countries and regions, including China, the United States, the European Union, Brazil, Australia, the United Kingdom, India, and Japan. It has been used in approximately 1,500 TKA procedures across more than 20 countries. MicroPort® MedBot™ remains committed to enhancing product competitiveness and clinical service standards through ongoing technological advancements and product optimization, providing high-quality solutions to medical institutions globally.



MicroPort® NeuroScientific Receives FDA Clearance for Its NUMEN™ Silk in the USA

On September 30, MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of MicroPort® NeuroScientific, received US FDA clearance for the NUMEN™ Silk Coil Embolization System (NUMEN™ Silk), marking its entry into the US market, its second international market after China.

NUMEN™ Silk is an upgraded version of the company's NUMEN™ Coil Embolization System (NUMEN™), which was first approved for marketing in China in September 2020 and has since received regulatory clearance in the US, and approvals in the EU, South Korea, Brazil, and Japan. NUMEN™ Silk is designed for the embolization of small to mid-sized aneurysms, micro-sized aneurysms, and ruptured aneurysms. Its "3-D" and "Ω+S" structure provides superior compliance with irregular aneurysm walls, and is available in a various diameters and lengths, offering more options for clinical application.

NUMEN™ Silk is a next-generation, ultra-soft, electrolytically detachable coil system with extra-fine primary coil wires that maintain coil softness, help to reduce pressure on the aneurysm wall, and lower the risk of rupture during surgery. Additionally, the pusher of NUMEN™ Silk features an ultra-soft distal end that increases flexibility, making it as soft as the coils themselves. This, combined with the ultra-short detaching zone, helps to reduce kick-back effects during the procedure, enabling smooth filling and resulting in safer and more effective aneurysm embolization.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com